Gene · 4593
Papers3,141
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 3,141
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report. | Hum Vaccin Immunother | 2023 | 37643747 | PubTator, text mining | PubMed |
| New mutation in the β1 propeller domain of LRP4 responsible for congenital myasthenic syndrome associated with Cenani-Lenz syndrome. | Sci Rep | 2023 | 37640745 | PubTator, text mining | PubMed |
| Association between COVID-19 and myasthenia gravis (MG): A genetic correlation and Mendelian randomization study. | Brain Behav | 2023 | 37638499 | PubTator, text mining | PubMed |
| Long-term muscle-specific overexpression of DOK7 in mice using AAV9-tMCK-DOK7. | Mol Ther Nucleic Acids | 2023 | 37637210 | PubTator, text mining | PubMed |
| D-Penicillamine-Induced Myasthenia Gravis-A Probable Complication of Wilson's Disease Treatment-A Case Report and Systematic Review of the Literature. | Life (Basel) | 2023 | 37629572 | PubTator, text mining | PubMed |
| Peripheral immune landscape for hypercytokinemia in myasthenic crisis utilizing single-cell transcriptomics. | J Transl Med | 2023 | 37620910 | PubTator, text mining | PubMed |
| Personality factors in patients with myasthenia gravis: A prospective study. | Brain Behav | 2023 | 37608592 | PubTator, text mining | PubMed |
| Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes. | Antibodies (Basel) | 2023 | 37606434 | PubTator, text mining | PubMed |
| FcRN receptor antagonists in the management of myasthenia gravis. | Front Neurol | 2023 | 37602255 | PubTator, text mining | PubMed |
| Therapeutic and prognostic features in myasthenia gravis patients followed in a tertiary neuromuscular diseases center in Turkey. | Front Neurol | 2023 | 37602241 | PubTator, text mining | PubMed |
| Fixed cell-based assays for autoantibody detection in myasthenia gravis: a diagnostic breakthrough. | Lancet Reg Health West Pac | 2023 | 37601007 | PubTator, text mining | PubMed |
| The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis. | J Transl Med | 2023 | 37592303 | PubTator, text mining | PubMed |
| IgG1-3 MuSK Antibodies Inhibit AChR Cluster Formation, Restored by SHP2 Inhibitor, Despite Normal MuSK, DOK7, or AChR Subunit Phosphorylation. | Neurol Neuroimmunol Neuroinflamm | 2023 | 37582613 | PubTator, text mining | PubMed |
| YAP/TAZ: Molecular pathway and disease therapy. | MedComm (2020) | 2023 | 37576865 | PubTator, text mining | PubMed |
| Impaired skeletal muscle health in Parkinsonian syndromes: clinical implications, mechanisms and potential treatments. | J Cachexia Sarcopenia Muscle | 2023 | 37574254 | PubTator, text mining | PubMed |
| Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series. | Support Care Cancer | 2023 | 37572133 | PubTator, text mining | PubMed |
| Genetically predicted effects of physical activity and sedentary behavior on myasthenia gravis: evidence from mendelian randomization study. | BMC Neurol | 2023 | 37568096 | PubTator, text mining | PubMed |
| Autoimmune myasthenia gravis and COVID-19. A case report-based review. | J Int Med Res | 2023 | 37565671 | PubTator, text mining | PubMed |
| Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease. | Front Immunol | 2023 | 37564637 | PubTator, text mining | PubMed |
| Myasthenia gravis and congenital myasthenic syndromes. | Handb Clin Neurol | 2023 | 37562891 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4593/papers?page=22